MedImmune | GenomeWeb

MedImmune

The pharma company will analyze genomic and clinical data from 2 million individuals over the next 10 years to drive drug development across its entire portfolio. 

Cepheid will create Xpert cartridge tests to detect S. aureus and P. aeuginosa, to be used in clinical trials for biologics intended to prevent pneumonia.

While the deal has provided AstraZeneca and MedImmune access to the tissue phenomics technology, Definiens now has broader and clearer access to patients.

 

NEW YORK (GenomeWeb) – AstraZeneca today announced its biologics research and development arm MedImmune has reached a deal to purchase digital pathology products firm Definiens.

NEW YORK (GenomeWeb) – AstraZeneca and its wholly owned subsidiary MedImmune announced on Thursday collaborations with the University of Cambridge, including one aimed at research into neurodegenerative diseases.

NEW YORK (GenomeWeb) — A group of pharmaceutical companies, research groups, foundations, and the clinical sequencing firm Foundation Medicine have joined to initiate a multi-drug, multi-arm, biomarker-driven clinical trial for patients with squamous cell carcinoma called the Lung Cancer Master P

NEW YORK (GenomeWeb) – Ventana today said that it is collaborating with MedImmune to develop a companion diagnostic for a drug MedImmune is developing for non-small cell lung cancer.

NEW YORK (GenomeWeb News) – The Montreal Heart Institute has partnered with several biotech companies and the Quebec government to launch a C$49.2 million (US$44.6 million) research program to that will use genetic and other biomarkers to develop personalized treatments for cardiovascular disease

NEW YORK (GenomeWeb News) – KineMed today announced an agreement with MedImmune to study the effects of a monoclonal antibody on the dynamics of the cellular prion protein.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.